Tom Alsaigh, MD, Laura Nicholson, MD, PhD, and Eric Topol, MD
Clinicians should have a working understanding of gene editing, controversy surrounding its use, and its far-reaching clinical and ethical implications.
AMA J Ethics. 2019;21(12):E1089-1097. doi:
10.1001/amajethics.2019.1089.
Despite drawbacks of immunosuppression and surgery, vascularized composite allotransplants can enhance lives of patients who meet candidacy criteria and are well supported.
AMA J Ethics. 2019;21(11):E968-973. doi:
10.1001/amajethics.2019.968.
Because regulatory approval of cognitive enhancement drugs is likely, physicians may want to consider whether they would condone the practice for restoration of function only or for enhancement purposes as well.
Does a surgeon’s complication rate in a randomized controlled trial constitute a “significant new finding” that must be reported to patients during the consent process?